Regeneron Faces Class Action Suit Over Alleged Securities Fraud
News related to:Regeneron Pharmaceuticals, Inc · 2 min read
Regeneron Pharmaceuticals, Inc., a leading pharmaceutical company, faces a class action lawsuit over alleged securities fraud. The lawsuit, captioned Cheatham v. Regeneron Pharmaceuticals, Inc., No. 26-cv-06026 (S.D.N.Y.), accuses the company and certain top executives of violating the Securities Exchange Act of 1934.
According to the complaint, Regeneron made false and misleading statements during the period from August 1, 2025, to May 15, 2026. Specifically, the lawsuit alleges that the company created a false impression that its Phase III Fianlimab-Libtayo Study was well-positioned for success, while downplaying the risks to the study's primary endpoint and overall statistical validity. The complaint also claims that the company's preliminary statistical assumptions were fundamentally flawed, and that the active treatment arm was failing to achieve meaningful clinical differentiation over standard therapies.
On April 29, 2026, during Regeneron's first quarter earnings call, the company disclosed that the Phase III Fianlimab-Libtayo Study had been altered, expanding the number of patients eligible for "analysis of progression-free survival." This news caused the price of Regeneron stock to decline by more than 6%.
Investors who purchased or acquired Regeneron common stock between August 1, 2025, and May 15, 2026, have until September 14, 2026, to seek appointment as lead plaintiff in the lawsuit. The Private Securities Litigation Reform Act of 1995 permits any investor who suffered substantial losses during this period to seek appointment as lead plaintiff.
Robbins Geller Rudman & Dowd LLP, a law firm known for representing investors in securities fraud and shareholder rights litigation, is handling the case. The firm has a track record of recovering significant sums for investors, including the largest ever recovery of $7.2 billion in In re Enron Corp. Sec. Litig.
The lawsuit highlights the importance of transparency and accurate disclosure in the pharmaceutical industry, where investors rely on detailed and reliable information to make informed decisions. The allegations against Regeneron suggest that the company may have misled investors about the status and potential of its clinical trials, potentially causing significant financial losses for shareholders.